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Understanding the temporal dynamics of COVID-19 patient phenotypes is necessary to derive fine-
grained resolution of pathophysiology. Here we use state-of-the-art deep neural networks over an 
institution-wide machine intelligence platform for the augmented curation of 15.8 million clinical 
notes from 30,494 patients subjected to COVID-19 PCR diagnostic testing. By contrasting the 
Electronic Health Record (EHR)-derived clinical phenotypes of COVID-19-positive (COVIDpos, n=635) 
versus COVID-19-negative (COVIDneg, n=29,859) patients over each day of the week preceding the 
PCR testing date, we identify anosmia/dysgeusia (37.4-fold), myalgia/arthralgia (2.6-fold), diarrhea 
(2.2-fold), fever/chills (2.1-fold), respiratory difficulty (1.9-fold), and cough (1.8-fold) as significantly 
amplified in COVIDpos over COVIDneg patients. The specific combination of cough and diarrhea has 
a 3.2-fold amplification in COVIDpos patients during the week prior to PCR testing, and along with 
anosmia/dysgeusia, constitutes the earliest EHR-derived signature of COVID-19 (4-7 days prior to 
typical PCR testing date). This study introduces an Augmented Intelligence platform for the real-
time synthesis of institutional knowledge captured in EHRs. The platform holds tremendous 
potential for scaling up curation throughput, with minimal need for retraining underlying neural 
networks, thus promising EHR-powered early diagnosis for a broad spectrum of diseases.  
 
Coronavirus disease 2019 (COVID-19) is a respiratory infection caused by the novel Severe Acute 
Respiratory Syndrome coronavirus-2 (SARS-CoV-2). As of April 28, 2020, according to WHO there have 
been nearly 3 million confirmed cases worldwide and more than 200,00 deaths attributable to COVID-19 
(https://covid19.who.int/). The clinical course and prognosis of patients with COVID-19 varies substantially, 
even among patients with similar age and comorbidities1. Following exposure and initial infection with 
SARS-CoV-2, likely through the upper respiratory tract, patients can remain asymptomatic although active 
viral replication may be present for weeks before symptoms manifest1,2. The asymptomatic nature of initial 
SARS-CoV-2 infection in the majority of patients may be exacerbating the rampant community transmission 
observed3. It remains unknown which patients become symptomatic, and in those who do, the timeline of 
symptoms remains poorly characterized and non-specific. Symptoms may include fever, fatigue, myalgias, 
loss of appetite, loss of smell (anosmia), and altered sense of taste, in addition to the respiratory symptoms 
of dry cough, dyspnea, sore throat, and rhinorrhea, and well as gastrointestinal symptoms of diarrhea, 
nausea, and abdominal discomfort4. A small proportion of COVID-19 patients progress to severe illness 
requiring hospitalization or intensive care management; among these individuals, mortality owing to Acute 
Respiratory Distress Syndrome (ARDS) is higher5. The estimated average time from symptom-onset to 
resolution can range from three days to more than three weeks, with a high degree of variability6. The 
COVID-19 public health crisis demands a data science-driven and temporal pathophysiology-informed 
precision medicine approach for its effective clinical management. 
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Here we introduce a platform for the augmented curation of the full-spectrum of patient phenotypes 
from 15,775,993 clinical notes of the Mayo Clinic EHRs for 30,494 patients with confirmed positive/negative 
COVID-19 diagnosis by PCR testing (see Methods). The platform utilizes state-of-the-art transformer 
neural networks on the unstructured clinical notes to automate entity recognition (e.g. diseases, drugs, 
phenotypes), quantify the strength of contextual associations between entities, and characterize the nature 
of association into positive, negative, or other sentiments. We identify specific gastro-intestinal, respiratory, 
and sensory phenotypes, as well as some of their specific combinations, that appear to be indicative of 
impending COVIDpos diagnosis by PCR testing. This highlights the potential for neural networks-powered 
EHR curation to facilitate a significantly earlier diagnosis of COVID-19 than currently thought feasible.  
 
Results 
The clinical determination of the COVID-19 status for each patient was conducted using the SARS-
CoV-2 PCR (RNA) test approved for human nasopharyngeal and oropharyngeal swab specimens under 
the U.S. FDA emergency use authorization (EUA)6. This PCR test resulted in 14,695 COVIDneg patient 
diagnoses and 635 COVIDpos patient diagnoses. In order to investigate the time course of COVID-19 
progression in patients, we used BERT-based deep neural networks to extract symptoms and their putative 
synonyms from the clinical notes for a few weeks prior to, and a few weeks post, the date when the COVID-
19 diagnosis test was taken (see Methods; Table 1). For the purpose of this analysis, all patients were 
temporally aligned, by setting the date of COVID-19 PCR testing to ‘day 0’, and the proportion of patients 
demonstrating each symptom derived from the EHR over each day of the week preceding and post PCR 
testing was tabulated (Table 2). As a negative control, we included a non-COVID-19 symptom ‘dysuria’. 
Altered or diminished sense of taste or smell (dysgeusia or anosmia) is the most significantly 
amplified signal in COVIDpos over COVIDneg patients in the week preceding PCR testing (Table 1; 37.4-fold 
amplification; p-value = 2.9E-187). This result suggests that anosmia and dysgeusia are likely the most 
salient early indicators of COVID-19 infection, including in otherwise asymptomatic patients. 
In the COVIDpos patients, diarrhea is significantly amplified in the week preceding PCR testing 
(Table 1; 2.2-fold; p-value = 3.9E-16). Some of these undiagnosed COVID-19 patients that experience 
diarrhea may be unintentionally shedding SARS-CoV-2 fecally7. Incidentally, epidemiological surveillance 
by waste water monitoring conducted recently in the state of Massachusetts observed copious SARS-CoV-
2 RNA8. The amplification of diarrhea in COVIDpos over COVIDneg patients in the week preceding PCR 
testing highlights the importance and necessity for washing hands often. 
Respiratory difficulty is enriched in the week prior to PCR testing in COVIDpos over COVIDneg 
patients (1.9-fold amplification; p-value = 1.1E-22; Table 1). Among other common phenotypes with 
significant enrichments in COVIDpos over COVIDneg patients, cough has a 1.8-fold amplification (p-value = 
9.3E-25), myalgia/arthralgia has a 2.6-fold amplification (p-value = 2E-24), and fever/chills has a 2.1-fold 
amplification (p-value = 1.3E-36). Rhinitis is also a potential phenotype of COVIDpos patients that requires 
some consideration (1.9-fold amplification, p-value = 1.3E-07). Conjunctivitis, hemoptysis, and respiratory 
failure have too few COVIDpos patients currently for them to be statistically meaningful enrichments, but 
these phenotypes are worth tracking (Table 1). Finally, dysuria was included as a negative control for 
COVID-19, and consistent with this assumption, 0.94% of COVIDpos patients and 0.93% of COVIDneg 
patients had dysuria during the week preceding PCR testing. 
Next, we considered the 351 possible pairwise conjunctions of 27 phenotypes for COVIDpos versus 
COVIDneg patients in the week prior to the PCR testing date (Table S1). As expected from the above results, 
altered sense of smell or taste (anosmia/dysgeusia) dominates in combination with many of the above 
symptoms as the most significant combinatorial signature of impending COVIDpos diagnosis (particularly 
along with cough, respiratory difficulty, fever/chills). Examining the other 325 possible pairwise symptom 
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combinations, excluding the altered sense of smell of taste, reveals other interesting combinatorial signals. 
The combination of cough and diarrhea is noted to be significant in COVIDpos over COVIDneg patients during 
the week preceding PCR testing; i.e. cough and diarrhea co-occur in 12.4% of COVIDpos patients and in 
3.9% of COVIDneg patients, indicating a 3.2-fold amplification of this specific symptom combination (BH 
corrected p-value = 4.0E-17, Table S1). 
We further investigated the temporal evolution of the proportion of patients with each symptom over 
the week prior to PCR testing (Table 2). Altered sense of taste or smell, cough, diarrhea, fever/chills, and 
respiratory difficulty were found to be significant discriminators of COVIDpos from COVIDneg patients 
between 4 to 7 days prior to PCR testing. During that time period, cough is amplified in the COVIDpos patient 
cohort over the COVIDneg patient cohort with an amplification of 3.9-fold (day -7, p-value = 1.4E-09), 4.33-
fold (day -6, p-value = 1.8E-12), 2.6-fold (day -5, p-value = 3.9E-04), and 2.2-fold (day -4, p-value = 8.4E-
03). The intriguing diminishing odds of cough as a symptom from 7 to 4 days preceding the PCR testing 
date, suggests this may be a notable temporal pattern. Likewise, diarrhea is amplified in the COVIDpos 
patient cohort over the COVIDneg patient cohort with an amplification of 3.2-fold (day -7, p-value = 4.1E-04), 
3.0-fold (day -6, p-value = 6.3E-04), 1.9-fold (day -5, p-value = 1.0E-01), and 1.2-fold (day -4, p-value = 
6.8E-01). Similarly, fever/chills is also enriched in the COVIDpos patient cohort over the COVIDneg patient 
cohort with 5.1-fold (day -7, p-value = 1.3E-12), 5.1-fold (day -6, p-value = 7.3E-15), 3.1-fold (day -5, p-
value = 2.2E-05), and 2.6-fold (day -4, p-value = 5.7E-04) amplifications. Respiratory difficulty is likewise 
enriched in day -7 (3.7-fold, p-value = 4E-07), day -6 (3.8-fold, p-value = 2.9E-08), and day -5 (2.7-fold, p-
value = 4.4E-04) among the COVIDpos patient cohort. Temporally subsequent to the enriched odds of 
diarrhea, cough, fever/chills, and respiratory difficulty, we find that change in appetite/intake is amplified in 
the COVIDpos cohort over the COVIDneg cohort on day -4 (6.3-fold, p-value = 2.2E-08), day -3 (6.0-fold, p-
value = 5.7E-08), and day -2 (4.6-fold, p-value = 5.9E-06). These observations characterize the temporal 
evolution of specific phenotypes that are enriched in COVIDpos patients, preceding and succeeding their 
PCR testing date. 
While explicit identification of SARS-CoV-2 in patients prior to the PCR testing date was not 
conducted, such prospective validation of our augmented EHR curation approach is being initiated. 
Nevertheless, this high-resolution temporal overview of the EHR-derived clinical phenotypes as they relate 
to the SARS-CoV-2 PCR diagnostic testing date for 30,494 patients has revealed specific enriched signals 
of impending COVID-19 onset. These clinical insights can help modulate social distancing measures and 
appropriate clinical care for individuals exhibiting the specific gastro-intestinal (diarrhea, change in 
appetite/intake), sensory (anosmia, dysgeusia) and respiratory phenotypes identified herewith, including 
for patients awaiting conclusive COVID-19 diagnostic testing results (e.g. by SARS-CoV-2 RNA RT-PCR). 
 
 
Discussion 
In order to identify potential cells and tissue types that may be associated with the EHR-derived 
clinical phenotypes observed above for COVID-19 patients, we analyzed Single Cell RNA-seq data using 
the nferX platform (see Methods)9. Given recent studies implicating the necessity of both ACE2 and 
TMPRSS2 for the SARS-CoV-2 lifecycle10, we scouted for human cells that co-express both genes. This 
co-expression analysis revealed that specific cell types from the small intestine/colon, nasal cavity, 
respiratory system, pancreas, urinary tract, and gallbladder co-express both ACE2 and TMPRSS2 (Figure 
1, Figure S1). Notably, multiple small intestine cell types co-express the two genes. These cell types include 
enterocytes, enteroendocrine cells, stem cells, goblet cells, and Paneth cells. In the pancreas, the cell types 
included ductal cells and acinar cells. The kidney cells co-expressing TMPRSS2 and ACE2 include proximal 
tubular cells, pelvic epithelial cells and type A intercalated cells. Co-expression of TMPRSS2 and ACE2 is 
also observed in the epithelial cells of the olfactory nasal cavity and the respiratory tract as well as in type 
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II pneumocytes (albeit at comparatively lower level). While the identified tissues showing co-expression of 
ACE2 and TMPRSS2 in the gastro-intestinal, respiratory, and sensory systems correlate with the clinical 
phenotypes of early COVID-19 infection as described above, these insights are conceivably from 
normal/healthy tissues. This highlight the need for meticulous bio-banking of COVID-19 patient-derived 
biospecimen and their characterization via single cell RNA-seq and other molecular technologies. 
Primary prevention is the most effective method to minimize spread of contagious infectious viruses 
such as SARS-CoV-2 (Figure S2). In addition to population-based strategies such as social distancing, 
there are significant ongoing efforts to develop a prophylactic solution (Table S2). As the immunodominant 
humoral immune response in patients is directed against the SARS-CoV2 spike protein, many vaccines 
under investigation target this viral protein. It remains to be determined whether anti-spike protein 
antibodies induced by natural infection or by vaccines induce neutralizing antibody responses. Chloroquine 
and its analogues have been shown to inhibit virus replication in-vitro28. Whether Chloroquine or 
Hydroxychloroquine have meaningful effects of SARS-CoV2 replication in patients remains to be 
understood, and are the subject of clinical trials, both as post-exposure prophylaxis and as treatment (Table 
S2). Hydroxychloroquine was approved by FDA for emergency use in hospitalized COVID-19 patients who 
are not eligible for clinical trials on April 7, 2020 based on limited clinical data, but concerns have been 
raised about toxicity and risk of sudden death29. 
Our findings from the EHR analysis of COVID-19 progression can aid in a human pathophysiology 
enabled summary of the experimental therapies being investigated for COVID-19 (Figure 2, Table S2). 
Some of the earliest phases of intervention attempt to inhibit the entry/replication of SARS-CoV-2 by 
modulating critical host targets (e.g. renin angiotensin aldosterone system/RAAS inhibitors, ACE2 analogs, 
serine protease inhibitors) or directly inhibiting the function of viral proteins (e.g. viral RNA-dependent RNA 
polymerase inhibitors, protease inhibitors, convalescent plasma, synthetic immunoglobulins) (Box 1, Table 
S3). In patients with more advanced stages of disease progression, who suffer from respiratory 
abnormalities, therapeutics are being advanced to target the inflammatory response that can lead to Acute 
Respiratory Disease Syndrome (ARDS) and is associated with high mortality (Box 1). These include anti-
GM-CSF agents, anti-IL-6 agents, JAK inhibitors, and complement inhibitors. Another emerging option for 
patients at this stage is convalescent plasma, which has shown some clinical benefits in cases of COVID-
19 and related viral diseases (SARS-1, MERS) at various stages of severity (Box 1). Administration of 
convalescent plasma containing active specific antiviral antibodies may prevent or attenuate progression 
to severe disease. Expanded access to convalescent plasma for treatment of patients with COVID-19 has 
been approved by the FDA for emergency IND use and is available through a nationwide program led by 
Mayo Clinic (Box 1).  
In those who become symptomatic, it is imperative that diagnostic testing is done, at dedicated 
testing sites if available, to confirm diagnosis (Figure S2). Meanwhile, patients are recommended to self-
quarantine at home, use mask protection when social distancing cannot be obtained, and continue 
supportive measures. For patients with mild symptoms, such measures may be sufficient given the self-
limited nature of viral syndromes. In the event of symptom exacerbation, often marked by worsening 
respiratory distress, medical evaluation is warranted, and possible hospitalization. The mainstay of 
treatment for COVID-19, remains supportive care, and as needed supplemental oxygen. Experimental 
therapies intended to block SARS-CoV2 viral entry and inhibit steps in the viral life cycle necessary for viral 
replication have been proposed at this early stage (Figure 2). The goal of these therapies is to reduce viral 
load, thus reducing the chance of overwhelming immune reaction by delaying progression of the disease.   
Among the proposed treatment options for COVID-19, corticosteroid should be avoided outside a 
clinical trial, as suggested by the IDSA, until further clinical evidence can be established 
(www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management). This is because 
there has been conflicting evidence and guidance on steroid use in COVID-1930. While steroids can play a 
 5 
role in control of inflammation, a collection of clinical evidence from steroid use in other coronavirus 
outbreaks suggest that the use of corticosteroids might exacerbate COVID-19-associated lung injury31.  
As patients progress to severe or critical diseases, the primary objective of COVID-19 management 
is to provide respiratory support and control immune overactivation (Figure 3, Figure S3). Patients whose 
condition deteriorates to critical status primarily decompensate from a respiratory standpoint, but may also 
develop multi-organ failure (respiratory failure, cardiac failure, renal failure, hypercoagulable state, 
thrombotic microangiopathy), as well as severe inflammatory responses similar to cytokine release 
syndrome and eventually reactive hemophagocytic lymphohistiocytosis syndrome. A major manifestation 
of respiratory decompensation and cytokine release syndrome is acute respiratory distress syndrome 
(ARDS). Critical care support such as mechanical support from noninvasive to invasive mechanical 
ventilation and in, some instances, extracorporeal support, vasopressors, renal replacement therapy, 
anticoagulation, and are paramount to survival of these critically ill patients per SCC guidelines 
(SCCM/ESICM 2020). On the other hand, drugs such as immunomodulatory agents often used to treat 
cytokine release syndrome, may allow for some degree of improvement or recovery either leading into or 
during severe and critical disease (Figure 2). 
This study demonstrates how the highly unstructured institutional knowledge can be robustly 
synthesized using deep learning and neural networks32. We started by leveraging a BERT-based deep 
neural network that was trained on ~18500 sentences containing 250 different phenotypes and symptoms 
related to cardiovascular, pulmonary, and cardiopulmonary diseases. We found that the model was 
translatable to the COVID-19 context, achieving an overall 92.7% true positive rate (see Methods and 
Table S5 for variations across symptoms). While these results speak to the scalability of our deep learning-
based approach to teaching machines how to read and comprehend de-identified clinical text, rigorous 
statistical assessments of neural network performance across disease areas will be essential to further 
advancing diagnostic applications for clinical care. 
Expanding beyond one institution’s COVID-19 diagnostic testing and clinical care to the EHR 
databases of other academic medical centers and health systems will provide a more comprehensive view 
of clinical phenotypes enriched in COVIDpos over COVIDneg patients in the days preceding confirmed 
diagnostic testing. This requires leveraging a privacy-preserving federated software architecture that 
enables each medical center to retain the span of control of their de-identified EHR databases, while 
enabling the machine learning models from partners to be deployed in their secure cloud infrastructure. 
Such seamless multi-institute collaborations over an Augmented Intelligence platform that puts patient 
privacy and HIPAA-compliance first, is being advanced actively over the Mayo Clinic’s Clinical Data 
Analytics Platform Initiative (CDAP). The capabilities demonstrated in this study for rapidly synthesizing 
over 8.2 million unstructured clinical notes to develop an EHR-powered clinical diagnosis framework will be 
further strengthened through such a universal biomedical research platform.  
A caveat of relying solely on EHR inference is that mild phenotypes that may not lead to a 
presentation for clinical care, such as anosmia, may go unreported in otherwise asymptomatic patients. 
However, the augmented curation approach described here allows for the active monitoring of all such 
symptoms as they emerge in the EHR; this may accelerate the identification of novel disease 
symptomatology. As a case in point, the CDC recently expanded its list of possible symptom indicators of 
COVID-19 to include new loss of taste or smell, headache, muscle pain, and repeated shaking with chills 
(www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html). As awareness of these 
symptoms grows, we expect their presence in the EHR to also grow, making statistical enrichment 
observations, such as those presented here, more robust. Another salient consideration is that as serology-
based tests for COVID-19 with high sensitivity and specificity are approved, testing will become more 
aggressive and “day 0” as defined in the present work will likely occur earlier in the COVID-19 illness course. 
Additionally, as at-home serology-based testing is advanced, capturing symptoms that precede clinical 
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testing will become increasingly important in order to facilitate the continued development and refinement 
of disease models; EHR-integrated digital health tools may help address this need. Finally, as multiple 
COVID-19 testing approaches are pursued and patients begin to receive multiple tests of different types, it 
will be important to leverage EHR curation tools to assess false positive rates of early serology testing and 
to gain insight into and optimize test sequencing. 
As we continue to understand the diversity of COVID-19 patient outcomes through holistic inference 
of EHR systems, it is equally important to invest in uncovering the molecular mechanisms and gain 
cellular/tissue-scale pathology insights through large-scale patient-derived biobanking and multi-omics 
sequencing. As the anecdotal single cell RNA-seq (scRNA-seq) based co-expression analysis of ACE2 and 
TMPRSS2 on normal human samples conducted here highlights, the rich heterogeneity of cell types 
constituting various host tissues can be investigated in great detail by scRNA-seq. To correlate patterns of 
molecular expression from scRNA-seq with EHR-derived phenotypic signals of COVID-19 disease 
progression, a large-scale bio-banking system has to be created. Such a system will enable deep molecular 
insights into COVID-19 to be gleaned and triangulated with SARS-CoV-2 tropism and patient outcomes.  
Ultimately, connecting the dots between the temporal dynamics of COVIDpos and COVIDneg clinical 
phenotypes across diverse patient populations to the multi-omics signals from patient-derived bio-specimen 
will help advance a more holistic understanding of COVID-19 pathophysiology. This will set the stage for a 
precision medicine approach to the diagnostic and therapeutic management of COVID-19 patients. 
 
BOX 1 
Experimental therapies targeting entry and 
replication of SARS-CoV-2 
RAAS inhibitors and ACE2 analogs: One class of 
experimental therapies intended to inhibit viral entry 
and early disease in COVID-19 includes Renin 
Angiotensin Aldosterone System (RAAS) inhibitors 
and recombinant ACE2 (Table S2). ACE2 is the 
primary host receptor for SARS-CoV-2, while serine 
protease TMPRSS2 is implicated in the spike protein 
priming after viral binding10. Recombinant ACE2 has 
been proposed as an early COVID-19 therapy based 
on in-vitro data11. At this time, the effect of RAAS 
inhibitors is uncertain in the context of COVID-19. 
Studies have investigated how ACE expression is 
modulated by coronavirus infection, and how that 
relates to lung injury11. Trials are ongoing with 
Angiotensin Receptor Blockers (ARBs) for treatment 
of COVID-19 by diminishing downstream harmful 
effects of angiotensin receptor activation (Figure 2). 
Serine Protease inhibitors: Given the TMPRSS2 
involvement in viral entry (Figure 2), serine protease 
inhibitors such as Camostat are now under evaluation 
in trials and should also be considered in the early 
stages of SARS-CoV-2 infection. 
Viral RNA-dependent RNA polymerase inhibitors: 
Of these, Remdesivir, a nucleoside analog, has 
attracted much attention for in-vivo inhibition of SARS-
CoV-2, and a recent observational study of 53 patients 
who received Remdesivir under compassionate use 
found that 68% of patients demonstrated improvement 
in respiratory status after a 10 day regimen12. Another 
nucleoside analog, Galidesivir, is also under 
evaluation in patients. Yet another viral replication 
inhibitor in clinical trials is Favipiravir (Figure 2). 
Favipiravir is a broad-spectrum viral RNA dependent 
RNA polymerase inhibitor that is shown to have in-vivo 
activity against a wide range of RNA viruses. In one 
RCT of 240 patients, Favipiravir was found to improve 
the clinical recovery rate of COVID-19 relative to 
Umifenovir, a viral entry inhibitor13 (Table S2). 
HIV Protease inhibitors: This class of medication is 
widely proposed and used off-label based on 
postulates that HIV and HCV proteases share 
structural similarities with those of SARS-CoV-214.  Of 
these, Lopinavir/Ritonavir (combination) has shown 
promise but was found to have a non-significant 
benefit in a Randomized Clinical Trial (RCT) of 199 
patients in China15, while Darunavir has shown no 
significant activity against SARS-CoV-2 in-vitro (Table 
S2)16. Multiple randomized, controlled clinical trials are 
now underway in the USA to determine efficacy of 
these drugs in the treatment of COVID-19.  
Other Antiviral Agents: Another emerging option for 
patients at this stage is convalescent plasma (Figure 
2), which has shown clinical benefits in cases of 
COVID-1917 and related viral diseases (SARS-1, 
MERS) at various stages of severity18,19. 
Administration of convalescent plasma containing 
specific antiviral antibodies may prevent or attenuate 
progression to severe disease. Expanded access to 
convalescent plasma for treatment of patients with 
COVID-19 is available through a program led by Mayo 
Clinic20. Synthetic hyperimmune globulins are also 
under development and evaluation. 
Agents being advanced that target the 
inflammatory response in COVID-19 
Anti-GM-CSF agents -- A xenograft study found that 
granulocyte monocyte colony stimulating factor (GM-
CSF) neutralization with Lenzilumab significantly 
reduced production of inflammatory cytokines21, 
offering evidence for efficacy of anti-GM-CSF agents 
in prevention of CART-induced cytokine release 
syndrome (CRS). Lenzilumab has been approved by 
the FDA for emergency IND use for CRS in COVID-19, 
while others such as Mavrilimumab and Gimsilumab 
aimed at controlling undesired inflammation from 
myeloid activation will be evaluated in clinical trials. 
 
Anti-IL-6 agents: IL-6 is a pro-inflammatory cytokine, 
regarded as a driver of CRS22 (Figure 2A-C). A recent 
report suggests IL-6 as a biomarker for respiratory 
failure in COVID-1922. As such, anti-IL-6 agents 
including Tocilizumab, Sarilumab, and Siltuximab are 
being evaluated in randomized trials (Table S2) and 
used off-label in severe COVID-19 patients. 
Tocilizumab was approved for the treatment of CRS in 
2017. An observational study of 21 patients with severe 
COVID-19 pneumonia treated with Tocilizumab 
showed promising results23,24.  
Anti-JAK agents: A number of immunomodulatory 
agents not linked to CRS are also under trial for COVID-
19 (Figure 2). Janus kinase (JAK) inhibitors such as 
Baricitinib, Fedratinib, and Ruxolitinib, indicated for 
Rheumatoid Arthritis and Myelofibrosis, have been 
tested in xenograft models for Chimeric Antigen 
Receptor (CAR) T-cell therapy induced CRS25. 
Ruxolitinib is available under an expanded access 
program in USA for severely ill COVID-19 patients 
(Table S1) and trials are underway in other countries. 
Anti-Complement agents: A recent study found that 
SARS-CoV-2 also binds to MASP2, a key driver of the 
complement activation pathway, leading to 
complement hyperactivation in COVID-19 patients26.  
Inhibitors of the terminal complement pathway such as 
Eculizumab have been tried in individuals with 
improvements observed after administration in China. 
Agents targeting ventilation/perfusion 
defects in COVID-19-induced ARDS 
Vasodilators: A recent report based on 16 cases in 
Italy and Germany noted that, contrary to the 
established understanding in ARDS, COVID-19 
patients in ARDS retain relatively high lung 
compliance27 and demonstrate ventilation/perfusion 
defects likely arising from perfusion dysregulation and 
hypoxic vasoconstriction.  Therefore, patients with 
COVID-19 in ARDS may benefit from vasodilators to 
address this pathophysiologic mechanism. A trial is 
underway in China for use of inhaled nitric oxide in 
patients with mechanical ventilation (Table S2). 
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Methods 
Augmented curation of EHR patient charts 
The nferX Augmented Curation technology was leveraged to rapidly curate the charts of SARS-
CoV-2-positive patients. First, we read through the charts of 100 patients and identified and grouped 
symptoms into sets of synonymous words and phrases. For example, “SOB”, “shortness of breath”, and 
“dyspnea”, among others, were grouped into “shortness of breath”. We did the same for diseases and 
medications. For the SARS-CoV2-positive patients, we identified a total of 26 symptom categories (Table 
S4) with 145 synonyms or synonymous phrases. Together, these synonyms and synonymous phrases 
capture a multitude of ways that symptoms related to COVID-19 are described in the Mayo Clinic Electronic 
Health Record (EHR) databases.  
Next, for charts that had not yet been manually curated, we used state-of-the-art BERT-based 
neural networks32 to classify symptoms as being present or not present based on the surrounding 
phraseology. The neural network used to perform this classification was trained using nearly 250 different 
phenotypes and 18,500 sentences; it achieves over 96% recall for positive/negative sentiment classification 
(Table S6). We went through individual sentences and either accepted the sentences or rejected and 
reclassified them. The neural networks were actively re-trained as curation progressed, leading to stepwise 
increases in curation efficiency and model accuracy. In Step 1 of this process, we labeled 11433 sentences, 
8737 of which were labeled as either ‘present’ or ‘not present.’ The model trained on this data set (90%-
10% training/test split) achieved F1 scores of 0.93 and 0.84 for ‘present’ and ‘not present’ classifications, 
respectively.  The model was then applied to an additional 3688 sentences in Step 2, rapidly corrected by 
a human for classification errors and re-trained to generate a newer version of the model. Step 3 was an 
iteration of step 2 on an additional 3369 sentences. The model achieved F1 scores of 0.96/0.91 after step 
2 and 0.96/0.96 after step 3 for the classification of ‘present’/’not present.’ Due to the augmented nature of 
this approach, steps 2 and 3 required successively less input from the human annotator.  
This model was applied to 15,775,993 clinical notes across 635 COVIDpos patients and 29,859 
COVIDneg patients. First, the difference between the date on which a particular note was written and the 
PCR testing date of the patient corresponding to that note formed the relative date measure for that note. 
The PCR testing date was treated as ‘day 0’ with notes preceding it assigned ‘day-1’, ‘day-2’ and so on. 
BERT-based neural networks were applied on each note to provide a set of symptoms that were present 
at that point of time for the patient in question. This map was then inverted to determine for each symptom 
and relative date the set of unique patients experiencing that symptom.  
Because the model had not yet encountered many COVID-19-related symptoms (Table S4), we 
performed a validation step in which the classifications of 4000 such sentences from the timeframe of 
highest interest (day 0 to day -7) were manually verified. Sentences arising from templates, such as patient 
education documentation, accounted for 10.2% of sentences identified. These template sentences were 
excluded from the analysis. The true positive rate (TPR), defined as the total number of correct 
classifications by the model divided by the number of total classifications, achieved by the model for 
classifying all symptoms was 92.7%; the corresponding false positive rate (FPR) was 13.4%. The model 
achieved true positive rate (TPR) ranging from 91% to 100% for the major symptom categories of 
Fever/Chills, Cough, Respiratory Difficulty, Headache, Fatigue, Myalgia/Arthralgia, Dysuria, Change in 
appetite/intake, and Diaphoresis. Classification performance was lower for Altered or diminished sense of 
taste and smell; here, the true positive rate was 64.4%. Detailed statistics are displayed in Table S5.  
For each synonymous group of symptoms, we computed the count and proportion of COVIDpos and 
COVIDneg patients that were deemed to have that symptom in at least one note between 1 and 7 days prior 
to their PCR test. We additionally computed the ratio of those proportions which indicates the extent of 
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prevalence of the symptom in the COVIDpos cohort as compared to the COVIDneg cohort. A standard 2-
proportion z hypothesis test was performed, and a p-value was reported for each symptom. 
To capture the temporal evolution of symptoms in the COVIDpos and COVIDneg cohorts, the process 
described above was repeated considering counts and proportions for each day independently. 
Pairwise analysis of phenotypes was performed by considering 351 phenotypic pairs from the 
original set of 27 individual phenotypes. For each pair, we calculated the number of patients in the COVIDpos 
and COVIDneg cohorts wherein both phenotypes occurred at least once in the week preceding PCR testing. 
With these patient proportions, a Fisher exact test p-value was computed. Benjamini-Hochberg correction 
was applied to account for multiple hypothesis testing. 
 
This research was conducted under IRB 20-003278, “Study of COVID-19 patient characteristics 
with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions”. 
All analysis of EHRs was performed in the privacy-preserving environment secured and controlled by the 
Mayo Clinic. nference and the Mayo Clinic subscribe to the basic ethical principles underlying the conduct 
of research involving human subjects as set forth in the Belmont Report and strictly ensures compliance 
with the Common Rule in the Code of Federal Regulations (45 CFR 46) on Protection of Human Subjects. 
 
 
Analysis of cell-types expressing ACE2 and TMPRSS2 using single cell RNAseq  
Since the successful entry of virus in the cell requires priming by cellular host protease – TMPRSS2, 
we hypothesized that cells that express both TMPRSS2+ and ACE2+ cells could harbor SARS-CoV-2 
during the course of infection. Thus, we probed for the expression of ACE2 and TMPRSS2 in all the single-
cell studies from human tissues available on the nferX Single Cell platform (https://academia.nferx.com/). 
For all the tissues that we profiled, we ensured that there is a minimum of 100 cells in the cell population 
and that there is a minimum of 1% of the cells in the cell population co-expressing (non-zero expression) 
both TMPRSS2 and ACE2 expression.  
 
Figure Legends 
Figure 1. Clinical phenotypes of COVID-19 and their connection to single cell RNA-seq co-
expression of ACE2-TMPRSS2. Severity of COVID-19 and associated clinical conditions are shown. Cell 
types co-expressing SARS-CoV-2 infectivity determinants ACE2 and TMPRSS2 determined by single cell 
RNA-seq are mapped onto the COVID-19 pathophysiology summary. 
Figure 2. Pathophysiology of COVID-19, associated treatments, and the underlying molecular 
mechanisms. While there is no established treatment strategy for COVID-19, several classes of 
therapeutics have emerged for the medical management of the disease, on the basis of their known 
mechanisms of action and the pathophysiology of COVID-19. 
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Table 1. Augmented curation of the unstructured clinical notes from the EHR reveals specific clinically 
confirmed phenotypes that are amplified in COVIDpos patients over COVIDneg patients in the week prior to the 
SARS-CoV-2 PCR testing date. The key COVIDpos amplified phenotypes in the week preceding PCR testing (i.e. day 
= -7 to day = -1) are highlighted in gray (p-value < 1E-10). The ratio of COVIDpos to COVIDneg proportions represents 
the fold change amplification of each phenotype in the COVIDpos patient set (phenotypes are sorted based on this 
column). Phenotypes highlighted with a superscript (*) are still rare in COVIDpos patients at this time, thus mitigating 
their statistical significance.  
 
Phenotype 
(p-value < 1E-10 in gray) 
COVID+ count 
(N=635) 
COVID- count 
(N = 29859) 
COVID+ 
proportion 
(N=635) 
COVID- 
proportion 
(N=29859) 
(COVID+/COVID-) 
relative ratio 
2-tailed 
p-value 
Altered or diminished 
sense of taste or smell 43 54 0.07 0.00 37.44 2.95E-187 
Conjunctivitis* 5 68 0.01 0.00 3.46 4.29E-03 
Myalgia/Arthralgia 105 1906 0.17 0.06 2.59 1.99E-24 
Diarrhea 101 2183 0.16 0.07 2.18 3.91E-16 
Fever / chills 230 5077 0.36 0.17 2.13 1.29E-36 
Respiratory difficulty 191 4680 0.30 0.16 1.92 1.08E-22 
Rhinitis 65 1614 0.10 0.05 1.89 1.28E-07 
Cough 236 6105 0.37 0.20 1.82 9.36E-25 
Cardiac 33 873 0.05 0.03 1.78 8.42E-04 
Respiratory Failure 26 717 0.04 0.02 1.71 6.17E-03 
Hemoptysis* 5 139 0.01 0.00 1.69 2.42E-01 
Diaphoresis 35 979 0.06 0.03 1.68 1.89E-03 
Change in appetite/intake 35 981 0.06 0.03 1.68 1.97E-03 
Headache 85 2449 0.13 0.08 1.63 2.83E-06 
Congestion 73 2228 0.11 0.07 1.54 1.40E-04 
Fatigue 93 3245 0.15 0.11 1.35 2.55E-03 
Neuro 50 2035 0.08 0.07 1.16 2.96E-01 
Pharyngitis 51 2129 0.08 0.07 1.13 3.83E-01 
Dysuria 6 277 0.01 0.01 1.02 9.64E-01 
Generalized symptoms 65 3502 0.10 0.12 0.87 2.47E-01 
Chest pain/pressure 49 2738 0.08 0.09 0.84 2.09E-01 
GI upset 67 3806 0.11 0.13 0.83 1.00E-01 
Dermatitis* 13 895 0.02 0.03 0.68 1.63E-01 
Otitis* 5 435 0.01 0.01 0.54 1.62E-01 
Wheezing 19 1917 0.03 0.06 0.47 4.56E-04 
Dry mouth 0 94 0.00 0.00 0.00 1.57E-01 
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Table 2. Temporal analysis of the EHR clinical notes for the week preceding PCR testing (i.e. day -7 to day -1), 
leading up to the day of PCR testing (day 0) in COVIDpos and COVIDneg patients. Temporal enrichment for each 
symptom is quantified using the ratio of COVIDpos patient proportion over the COVIDneg patient proportion for each day. 
The patient proportions in rows labeled ‘Positive (n = 635)’ and ‘Negative (n = 29859)’ are represented as percentages. 
 
Phenotype COVID-19 PCR (N = 30494) Day = -7 Day = -6 Day = -5 Day = -4 Day = -3 Day = -2 Day = -1 
Altered or diminished sense 
of taste or smell 
Positive (n = 635) 0.47% 0.31% 0.31% 0.16% 0.16% 0.00% 0.63% 
Negative (n = 29859) 0.01% 0.00% 0.01% 0.01% 0.01% 0.03% 0.08% 
Ratio (Positive/Negative) 70.53 - 23.51 15.67 15.67 0.00 7.84 
p-value 1.19E-19 3.08E-22 8.26E-08 1.33E-03 1.33E-03 6.45E-01 6.06E-06 
Cough 
Positive (n = 635) 2.83% 3.31% 2.05% 1.73% 1.73% 0.79% 12.60% 
Negative (n = 29859) 0.72% 0.76% 0.78% 0.79% 0.90% 1.19% 13.03% 
Ratio (Positive/Negative) 3.94 4.33 2.63 2.20 1.92 0.66 0.97 
p-value 1.40E-09 1.82E-12 3.88E-04 8.42E-03 3.07E-02 3.54E-01 7.50E-01 
Diarrhea 
Positive (n = 635) 1.42% 1.42% 0.94% 0.63% 0.63% 0.16% 5.20% 
Negative (n = 29859) 0.45% 0.47% 0.49% 0.51% 0.57% 0.67% 3.99% 
Ratio (Positive/Negative) 3.16 3.04 1.95 1.23 1.10 0.24 1.30 
p-value 4.08E-04 6.38E-04 1.03E-01 6.82E-01 8.50E-01 1.14E-01 1.24E-01 
Fever / chills 
Positive (n = 635) 2.68% 3.15% 2.05% 1.89% 1.57% 0.63% 11.65% 
Negative (n = 29859) 0.53% 0.61% 0.65% 0.71% 0.73% 1.03% 10.54% 
Ratio (Positive/Negative) 5.06 5.14 3.15 2.66 2.17 0.61 1.11 
p-value 1.33E-12 7.33E-15 2.20E-05 5.71E-04 1.39E-02 3.23E-01 3.66E-01 
Respiratory Difficulty 
Positive (n = 635) 2.20% 2.52% 1.89% 1.89% 1.10% 0.63% 7.87% 
Negative (n = 29859) 0.60% 0.66% 0.70% 0.68% 0.82% 1.07% 9.43% 
Ratio (Positive/Negative) 3.70 3.80 2.71 2.78 1.35 0.59 0.83 
p-value 3.96E-07 2.93E-08 4.39E-04 3.11E-04 4.31E-01 2.89E-01 1.83E-01 
Change in appetite/intake 
Positive (n = 635) 0.16% 0.16% 0.16% 1.26% 1.26% 1.26% 2.36% 
Negative (n = 29859) 0.15% 0.16% 0.18% 0.20% 0.21% 0.27% 1.45% 
Ratio (Positive/Negative) 1.02 0.96 0.89 6.27 5.97 4.59 1.63 
p-value 9.83E-01 9.67E-01 9.05E-01 2.17E-08 5.75E-08 5.93E-06 5.75E-02 
Respiratory failure 
Positive (n = 635) 0.63% 0.47% 0.47% 0.47% 0.16% 0.31% 1.26% 
Negative (n = 29859) 0.28% 0.27% 0.30% 0.30% 0.29% 0.33% 1.02% 
Ratio (Positive/Negative) 2.27 1.76 1.59 1.55 0.54 0.96 1.23 
p-value 9.99E-02 3.28E-01 4.28E-01 4.51E-01 5.34E-01 9.54E-01 5.62E-01 
Headache 
Positive (n = 635) 0.79% 1.26% 1.26% 0.79% 0.47% 0.16% 4.25% 
Negative (n = 29859) 0.39% 0.48% 0.49% 0.41% 0.45% 0.54% 4.13% 
Ratio (Positive/Negative) 2.03 2.65 2.58 1.93 1.06 0.29 1.03 
p-value 1.14E-01 5.19E-03 6.69E-03 1.42E-01 9.19E-01 1.93E-01 8.75E-01 
Fatigue 
Positive (n = 635) 1.10% 0.94% 0.94% 0.63% 0.47% 0.31% 5.51% 
Negative (n = 29859) 0.65% 0.73% 0.75% 0.73% 0.71% 1.00% 5.25% 
Ratio (Positive/Negative) 1.69 1.29 1.27 0.87 0.66 0.31 1.05 
p-value 1.67E-01 5.31E-01 5.67E-01 7.76E-01 4.74E-01 8.24E-02 7.68E-01 
Myalgia/Arthralgia 
Positive (n = 635) 0.94% 1.57% 1.26% 0.94% 0.47% 0.16% 5.67% 
Negative (n = 29859) 0.19% 0.20% 0.26% 0.23% 0.20% 0.33% 3.37% 
Ratio (Positive/Negative) 4.95 7.84 4.82 4.03 2.31 0.47 1.68 
p-value 3.46E-05 8.16E-13 2.66E-06 3.81E-04 1.44E-01 4.41E-01 1.56E-03 
Congestion 
Positive (n = 635) 0.79% 0.79% 0.94% 0.47% 0.47% 0.00% 2.68% 
Negative (n = 29859) 0.27% 0.30% 0.28% 0.28% 0.26% 0.38% 3.79% 
Ratio (Positive/Negative) 2.87 2.58 3.40 1.66 1.79 0.00 0.71 
p-value 1.65E-02 3.17E-02 2.05E-03 3.83E-01 3.17E-01 1.19E-01 1.44E-01 
Rhinitis 
Positive (n = 635) 0.79% 0.79% 0.63% 0.31% 0.16% 0.00% 2.36% 
Negative (n = 29859) 0.15% 0.19% 0.18% 0.16% 0.20% 0.26% 2.89% 
Ratio (Positive/Negative) 5.34 4.05 3.48 1.96 0.78 0.00 0.82 
p-value 6.76E-05 1.12E-03 1.02E-02 3.42E-01 8.08E-01 1.94E-01 4.34E-01 
Dysuria 
Positive (n = 635) 0.00% 0.00% 0.00% 0.00% 0.16% 0.00% 0.47% 
Negative (n = 29859) 0.04% 0.05% 0.04% 0.04% 0.05% 0.07% 0.41% 
Ratio (Positive/Negative) 0.00 0.00 0.00 0.00 2.94 0.00 1.16 
p-value 5.99E-01 5.60E-01 6.13E-01 6.29E-01 2.72E-01 4.94E-01 8.03E-01 
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SUPPLEMENTARY MATERIAL 
 
Figure S1. Cell-types connected to pathophysiology of COVID-19 as inferred from high expression 
of ACE2 and TMPRSS2 in human scRNA seq datasets. A scatter plot depicting the expression of ACE2 
and TMPRSS2 inferred from the single-cell RNA-seq profiling of human tissues using nferX single cell 
platform. The x-axis represents the mean ln(cp10k+1) expression of ACE2 in all the cells and the y-axis 
represents the mean ln(cp10k+1) expression of TMPRSS2 in the corresponding cell-types from respective 
tissues. The colors on the scatter plot depicts the tissue origins. The size of the points on the scatter plot 
represents the percentage of single cells in the cell-type that co-express ACE2 and TMPRSS2 (non-zero 
expression). 
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Figure S2. Disease progression of COVID-19 can be divided into multiple stages, and appropriate 
therapeutics can be chosen based on the specific pathophysiological mechanisms. Using nferX 
Knowledge Synthesis, the most associated molecular markers at each step of disease progression are also 
identified (see Supplementary Methods for details on nferX knowledge synthesis). In order to capture 
biomedical literature based associations, the nferX platform defines two scores: a “local score” and a “global 
score”, as described previously (Park, J. et al. Recapitulation and Retrospective Prediction of Biomedical 
Associations Using Temporally-enabled Word Embeddings. doi:10.1101/627513). 
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Figure S3. nferX-derived associations of COVID-19 treatment options to clinical phenotypes.  (A) 
Schematic of the derivation of nferX local and global scores quantifying associations between concepts 
from across the literature. (B) Heatmap of nferX Local Scores capturing associations discussed in the 
literature between select COVID-19 treatment drugs and COVID-19 related phenotypes. In order to capture 
biomedical literature-based associations, the nferX platform defines two scores: a “local score” and a “global 
score”, as described previously (Park, J. et al. Recapitulation and Retrospective Prediction of Biomedical 
Associations Using Temporally-enabled Word Embeddings. doi:10.1101/627513). 
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Table S1. Pairwise analysis of phenotypes in the COVIDpos and COVIDneg cohorts. The 
pairwise symptom combinations with p-value < 1E-06 are summarized. 
Phenotype 1 Phenotype 2 
COVID+ 
count 
(N=635) -- 
Only > 30 
shown 
COVID- 
count 
(N=29859) 
COVID+ 
% 
(N=635) 
COVID- % 
(N=29859) 
(COVID+)/(COVID-) 
ratio -- Only > 2.5 
shown 
raw p-
value -- 
Only < 
1E-06 
BH-
corrected 
p-value 
Altered or diminished 
sense of taste or 
smell 
Cough 38 31 5.98 0.10 57.64 9.22E-46 2.55E-43 
Fever / chills 
Altered or diminished 
sense of taste or 
smell 
37 32 5.83 0.11 54.37 5.47E-44 7.54E-42 
Fever / chills Respiratory difficulty 173 2558 27.24 8.57 3.18 7.46E-42 6.86E-40 
Fever / chills Cough 204 3490 32.13 11.69 2.75 3.35E-41 2.31E-39 
Altered or diminished 
sense of taste or 
smell 
Respiratory difficulty 34 29 5.35 0.10 55.13 1.22E-40 6.72E-39 
Fever / chills Myalgia/Arthralgia 86 1300 13.54 4.35 3.11 1.25E-19 3.45E-18 
Diarrhea Cough 79 1175 12.44 3.94 3.16 1.89E-18 4.00E-17 
Cough Myalgia/Arthralgia 82 1293 12.91 4.33 2.98 1.02E-17 2.02E-16 
Fever / chills Diarrhea 78 1238 12.28 4.15 2.96 9.87E-17 1.70E-15 
Diarrhea Myalgia/Arthralgia 43 502 6.77 1.68 4.03 1.05E-13 1.52E-12 
Respiratory difficulty Myalgia/Arthralgia 61 993 9.61 3.33 2.89 7.92E-13 1.04E-11 
Fever / chills Headache 76 1415 11.97 4.74 2.53 9.99E-13 1.25E-11 
Diarrhea Respiratory difficulty 59 1008 9.29 3.38 2.75 1.23E-11 1.48E-10 
Fever / chills Rhinitis 57 985 8.98 3.30 2.72 4.25E-11 4.88E-10 
Respiratory difficulty Rhinitis 50 799 7.87 2.68 2.94 5.59E-11 6.17E-10 
Respiratory difficulty Headache 62 1147 9.76 3.84 2.54 8.51E-11 9.03E-10 
Diarrhea Headache 37 602 5.83 2.02 2.89 2.92E-08 2.60E-07 
Rhinitis Headache 31 475 4.88 1.59 3.07 1.14E-07 9.82E-07 
Myalgia/Arthralgia Headache 41 760 6.46 2.55 2.54 1.91E-07 1.50E-06 
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Table S2. Collection of treatments undergoing clinical trials for COVID-19. 
Drug Class Drug Proposed Mechanism of Action NCT Number 
Renin-Angiotensin-
Aldosterone System 
(RAAS) Inhibitors 
and recombinant 
ACE2 
ACE inhibitors Inhibits viral entry and downstream activation of angiotensin mediated inflammation. Effects of ACE inhibition under evaluation 
NCT04330300, NCT04322786 
NCT04330300 
Angiotensin Receptor 
Blockers 
Inhibits angiotensin receptor. Given that SARS-CoV-2 uses ACE2 in viral entry, 
ARBs are under evaluation for potential efficacy and/or risk in COVID. 
NCT04335123, NCT04328012,and 
more 
Recombinant human 
ACE2 (rhACE2) 
SARS-CoV infection reduces ACE2 expression and that administration of 
recombinant ACE2 following infection can lead to reversal of lung injury NCT04287686, NCT04335136 
Antiviral Agents 
Remdesivir Nucleoside analog reported to improve respiratory status in 70% of patients (of 53 patients total) in an observation study. RCTs underway. 
NCT04292899, NCT04292730 and 
more 
Favipiravir Viral RNA polymerase inhibitor. RCT showed Favipiravir improved the clinical recovery rate of COVID relative to Umifenovir, a viral entry inhibitor 
NCT04336904, NCT04333589 and 
more 
Lopinavir/ritonavir Protease inhibitor used in HIV infection. Found to have a non-significant benefit in an RCT of 199 patients in China. Larger clinical studies in progress. 
NCT04295551, NCT04331470 and 
more 
Umifenovir Broad-spectrum antiviral that inhibits membrane fusion between virus and target hose. Initially developed for influenza. NCT04260594, NCT04273763 
Ribavirin Nucleoside analog with broad spectrum activity against RNA and DNA virus. NCT04276688 
Emtricitabine/tenofovir Nucleoside reverse-transcriptase inhibitor used for HIV infection being evaluated for COVID prevention in healthcare workers NCT04334928 
Oseltamivir sialidase used in influenza. Proposed for role of sialic acid in viral entry of coronavirus NCT02735707, NCT04261270 
DAS181 inhaled sialidase, initially developed for parainfluenza infection, proposed given the role of sialic acid in the viral entry of coronavirus 
NCT04324489, NCT04298060 and 
more 
Darunavir Protease inhibitor used in HIV infection, proposed for potential antiviral efficacy. NCT04252274 
ASC09 a novel protease inhibitor similar in structure to darunavir. Initially developed for HIV infection. NCT04261907 
Meplazumab Shown to bind to spike protein of SARS-CoV-2 and found to reduce severity of COVID in RCT of 17 patients in China 1 NCT04275245 
Interferon Beta-1A 
Shown to have in-vitro inhibitory activity against SARS-CoV22 NCT04315948, NCT02735707 and more 
Interferon Beta-1B 
Levamisole + 
Budesonide+ 
Formoterol inhaler 
Found to bind to Papaine Like Protease, which is implicated in SARS-CoV-2 
virulence NCT04331470 
Camostat Mesilate Serine protease proposed for in-vitro inhibition of MERS-CoV entry3 NCT04321096, NCT04338906 
Convalescent plasma Antibodies in recovered patients. Synthetic antibodies under development NCT04264858 
Anti-IL6 Agents 
Tocilizumab IL-6 inhibitor proposed to reduce risk of cytokine release syndrome in COVID NCT04317092, NCT04320615, and more 
Siltuximab IL-6 inhibitor proposed to reduce risk of cytokine release syndrome in COVID NCT04330638, NCT04329650 
Sarilumab IL-6R inhibitor proposed to reduce risk of cytokine release syndrome in COVID NCT04315298, NCT04324073, and more 
Complement 
Inhibitors 
Eculizumab 
proposed for anti-C5a activity to inhibit complement overactivation in COVID 
NCT04288713 
IFX-1 NCT04333420 
JAK Inhibitors 
Baricitinib 
JAK inhibitor proposed for anti-inflammatory activity to attenuate immune 
overactivation in severe COVID 
NCT04340232, NCT04320277 and 
more 
Tofacitinib NCT04332042 
Ruxolitinib NCT04337359, NCT04331665 and more 
Anti-GM-CSF Agents 
Mavrilimumab anti-GM-CSF agent proposed for anti-inflammatory effects in the event of COVID-induced cytokine release syndrome NCT04337216 
Lenzilumab anti-GM-CSF agent. Approved under emergency IND use.  
Gimsilumab anti-GM-CSF agent about to begin clinical trials.  
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Other Anti-
Inflammatory or Anti-
Fibrotic Agents 
 
 
Piclidenoson initially developed for rheumatoid arthritis. Binds to A3AR, which may attenuate CRS. Also shown to have antiviral activity against RNA virus4 NCT04333472 
Anakinra IL-1a antagonist initially developed for rheumatoid arthritis. NCT04330638, NCT04339712 
Emapalumab Anti-IFN gamma agent proposed for anti-inflammatory effect in combination with anakinra NCT04324021 
Thalidomide anti-TNF agent used in multiple myeloma and graft-versus-host diseases proposed for immunomodulatory effects NCT04273581 
Colchicine 
Proposed for inhibition of inflammation caused by NLRP3 inflammasome, through 
inhibition of tubulin polymerization, and potential effects on cellular adhesion 
molecules and inflammatory chemokines 
NCT04326790, NCT04328480 and 
more 
Fingolimod Immunomodulatory agent used in multiple sclerosis. NCT04280588 
Aviptadil Synthetic VIP peptide proposed for immunomodulatory effects5 NCT04311697 
BLD-2660 Selective CAPN inhibitor initially developed for pulmonary fibrosis. Studies found that CAPN inhibition led to reduce replication of SARS-CoV-16 NCT04334460 
Bevacizumab anti-VEGF antibody proposed to attenuate increases in vascular permeability in the COVID-induced vascular inflammation NCT04305106, NCT04275414 
Bromhexine Increases secretion of mucus components in the respiratory tract and alleviates respiratory inflammation.7 NCT04340349, NCT04273763 
CD24Fc Initially developed for GVHD Shown to reduce inflammation by binding to DAMP and Siglec G/10 to modulate immune response8 NCT04317040 
Carrimycin Under evaluation in China for efficacy against upper respiratory tract diseases NCT04286503 
Nintedanib tyrosine kinase inhibitor initially developed for idiopathic pulmonary fibrosis, likely approved for anti-inflammatory and anti-fibrotic activity NCT04338802 
PUL-042 TLR 2/6/9 agonist proposed to prevent COVID NCT04313023, NCT04312997 
Defibrotide Oligonucleotide initially approved in hepatic veno-occlusive diseases. Likely proposed for effect in modulation of endothelial injury. NCT04335201 
Ibrutinib BTK inhibitor used for B-cell malignancies, but also has activity against TEC family kinase. In-vivo evidence for lung protection in viral infection9  
Vasodilators or other 
agents targeting 
effects of hypoxic 
vasoconstriction 
Sildenafil Vasodilator likely proposed to attenuate perfusion dysregulation and hypoxic 
vasoconstriction in COVID ARDS 
NCT04304313 
Inhaled nitric oxide NCT04306393 
Sargramostim inhaled sargramostim, which induces hematopoiesis, proposed to attenuates acute hypoxic respiratory failure in COVID NCT04326920 
Vaccines 
mRNA-1273 Clinical trial sponsored by NIAID underway at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. NCT04283461 
INO-4800 Inovio announced an accelerated timeline for the development of the vaccine on 03 March. Trial underway. NCT04336410 
BCG Vaccine Suggested to be protective against COVID with limited data10 NCT04328441, NCT04327206 
Mesenchymal 
Stem Cell (MSC) 
Therapy 
NestCellÂ®, 
Human Umbilical 
Derived MSC l, 
Dental Pulp MSC, 
Wharton's Jelly-MSCs 
MSCs shown to reduce nonproductive inflammation and affect tissue regeneration 
and is being evaluated in patients with ARDS 
NCT04315987 
NCT04336254 
NCT04313322 
And more 
MSC + Ruxolitinib MSC+ ruxolitinib being evaluated in severe COVID-19 ChiCTR2000029580 
Exosomes allogeneic 
adipose MSC (MSCs-
Exo) 
Pilot pilot clinical trial  performed to explore the safety and efficiency of aerosol 
inhalation of the MSCs-Exo in patients with severe COVID-19 NCT04276987 
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Table S3. Disease Progression of COVID-19 and Associated Treatment 
Diseases 
Progression 
Symptoms and other Clinical Indicators Recommended Treatment 
Prior to or at time of 
Exposure 
Asymptomatic ● Vaccination, when available 
● Zinc Prophylaxis 
● Hydroxychloroquine Prophylaxis 
● Social Distancing 
● Self-Quarantine 
● Mask Protection 
Early Infection, 
without 
hospitalization 
Fever 
Anosmia/Ageusia 
Mild respiratory symptoms (cough, 
dyspnea, sore throat, rhinorrhea) 
GI symptoms (diarrhea, nausea, 
abdominal discomfort) 
 
Focal consolidation on CXR; Focal ground 
glass opacity on CT 
● Zinc 
● Hydroxychloroquine 
● Supportive Treatment (Hydration, Oxygen if 
needed) 
● Self-Quarantine 
● Antiviral agents (nucleoside analogs, viral 
polymerase and protease inhibitors, and 
others) 
● Viral entry or binding inhibitors (rhACE2, 
Camostat mesylate and others):  
Moderate diseases, 
requiring 
supplemental 
oxygen 
Persistent Fever 
Moderate respiratory and GI symptoms 
Dyspnea with increased oxygen 
requirement 
 
Oxygen desaturation (<93%) 
Diffuse Ground Glass Opacity on CT 
Chest 
● Oxygen supplementation (high flow nasal 
cannula, avoid BiPAP due to virus 
aerosolization) 
● Antiviral agents (nucleoside analogs, viral 
polymerase and protease inhibitors, and 
others) 
● Convalescent patient plasma or Synthetic 
immunoglobulin 
● CRS/Immune overactivation prophylaxis using 
anti-inflammatory agents 
● Anti-GM-CSF Agents 
● Anti-IL6 Agents 
● JAK Inhibitors 
Severe diseases 
requiring mechanical 
ventilation, with 
immune 
overactivation 
ARDS 
Cytokine Release Syndrome-like 
inflammatory response 
Multi-organ involvement 
 
Elevation of IL-6, Ferritin & other 
inflammatory markers 
 
Diffuse bilateral coalescent opacities 
Anti-Inflammatory agents, including 
● Anti-IL6 Agents 
● Complement Inhibitors 
● Anti-GM-CSF Agents 
● JAK Inhibitors 
● Anti-Fibrotic Agents 
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Table S4. Symptoms and their synonyms used for the EHR analysis. 
Symptom/Finding Synonyms/related entities identified in EHR 
Fever / chills fever, fevers, chill, chills, tactile fever, felt warm, subjective fever 
Altered or diminished sense of 
taste or smell 
change in smell, lost her sense of smell and taste, bitter taste in his mouth, no sense of taste or smell, no sense of smell or 
taste, decrease in smell, decreased sense of taste, change in her sense of taste and smell, decrease in smell and taste, 
ageusia, change in taste, lost her sense of taste and smell, dysgeusia, everything smells and tastes terrible, anosmia, altered 
smell, loss of taste and smell, change in his sense of smell and taste, altered sense of taste and smell, decrease in taste and 
smell, decreased taste, bitter taste in her mouth, taste is altered, lost his sense of smell, decreased smell, altered taste, 
altered sense of smell and taste, change in taste and smell, lost his sense of smell and taste, change in her sense of smell 
and taste, everything tastes and smells terrible, lost his sense of taste and smell, lost her sense of smell, loss of smell and 
taste, decrease in taste, decrease taste, bitter taste, no smell or taste, no taste or smell, anosmia/dysgeusia, decrease smell, 
change in smell and taste, change in his sense of taste and smell 
Diarrhea loose stools, soft stools, watery diarrhea, soft stool, diarrhea, watery bm, vomiting diarrhea, loose stool, diarrhea vomiting 
GI upset abdominal pain, nausea, abdominal cramping, posttussive emesis, stomach ache, emesis, vomiting, nausea vomiting 
abdominal pain, stomach cramping, vomiting diarrhea, diarrhea vomiting 
Wheezing wheezing 
Respiratory difficulty increased oxygen demands, lower respiratory symptoms, tachypnea, tachypneic, labored breathing, dyspnea with walking, 
dyspnea on exertion, shortness of breath, sob with exercise, dyspnea, sob 
Respiratory failure Respiratory failure 
Cough cough, cough that is nonproductive, productive cough, cough np p, dry cough, cough productive, cough that is productive, 
nonproductive cough, coughing, non productive cough 
Hemoptysis hemoptysis, blood-tinged sputum, red-tinged sputum 
Chest pain/pressure chest congestion, chest tightness, pleuritic chest pain, chest heaviness, chest pain, tightness of the chest, chest discomfort 
Congestion sinus pressure, congestion, head congestion, stuffy nose, congested, nasal congestion, congestion rhinorrhea, facial 
pressure, sinus congestion 
Rhinitis rhinitis, itchy eyes and nose, runny nose, tickling in nose, sniffles, rhinorrhea, sneezing, congestion rhinorrhea 
Myalgia/Arthralgia body ache, myalgia, muscle aches, arthralgias, sore neck, sore muscles, muscle discomfort, joints became sore, body aches, 
aches and pains, achy joints, arthralgia, myalgias], Generalized symptoms: [weakness, feeling run down, cold, malaise, 
generalized weakness, influenza like symptoms, weak, feeling poorly 
Generalized symptoms cold, generalized weakness, malaise, weakness, weak, influenza like symptoms, feeling run down, activity change 
Fatigue fatigued, energy level is diminished, lethargy, fatigue, energy level is poor, activity change, sleeping more than usual, 
lethargic 
Diaphoresis diaphoretic, diaphoresis, night sweats, sweaty, sweating, sweats 
Pharyngitis scratchy throat, throat discomfort, tingly throat, throat irritation, sore throat 
Headache headache, HA, headaches, HA's, sinus headache 
Dry mouth dry mouth, xerostomia 
Change in appetite/intake decrease in appetite, diminished appetite, appetite is poor, appetite change, appetite is diminished, appetite has been 
fluctuating, poor appetite, decreased appetite, anorexia, not eating and drinking, little appetite, no appetite, not eating or 
drinking 
Conjunctivitis itchy eyes and nose, red eyes, watery eyes, pink eye, red eye, watery eyes with redness 
Neuro agitation, vision trouble, dizziness, confusion, delirium, agitated 
Cardiac palpitations, lightheadedness 
Otitis earache, ear ache, ear pain 
Dermatitis rash 
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Table S5. Synonym classification model performance 
Symptom(s) Total # sentences 
% from 
template 
Overall 
accuracy 
True Pos 
Rate 
False Neg 
Rate 
COMBINED 4001 10.2 0.874 0.927 0.167 
Fever / chills 915 13.4 0.857 0.926 0.145 
Cough 913 11.6 0.855 0.918 0.265 
Respiratory difficulty 751 13.7 0.871 0.941 0.103 
Diarrhea 440 17.3 0.899 0.913 0.15 
Respiratory failure 202 0 0.985 0.995 0.5 
Headache 199 0 0.852 0.942 0.115 
Fatigue 198 0 0.914 0.971 0.25 
Altered or diminished sense of taste or 
smell 166 0 0.728 0.644 0.361 
Myalgia/Arthralgia 78 0 0.928 0.976 0.038 
Dysuria 69 0 0.956 1 0 
Change in appetite/intake 67 0 0.924 0.915 0.417 
Diaphoresis 3 0 1 1 0 
 
 
 
Table S6. Performance of the BERT symptom classifier 
 
 
